Inflammatory Bowel Diseases最新文献_第7页

Disparities in Access and Treatment for Rural Patients With Inflammatory Bowel Disease: A Survey of Inflammatory Bowel Disease Patients and Providers. 农村炎症性肠病患者可及性和治疗的差异：对炎症性肠病患者和提供者的调查。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-08 DOI: 10.1093/ibd/izaf090

Timothy McAuliffe, Jessica K Salwen-Deremer, Corey A Siegel

{"title":"Disparities in Access and Treatment for Rural Patients With Inflammatory Bowel Disease: A Survey of Inflammatory Bowel Disease Patients and Providers.","authors":"Timothy McAuliffe, Jessica K Salwen-Deremer, Corey A Siegel","doi":"10.1093/ibd/izaf090","DOIUrl":"https://doi.org/10.1093/ibd/izaf090","url":null,"abstract":"Background: With the increasing complexity of inflammatory bowel disease (IBD) care, the integration of IBD specialist gastroenterologists and multidisciplinary teams (MDTs) is becoming more important. However, access to these services is not widely available. This study sought to evaluate the needs of rural and urban IBD patients and providers in the setting of complex IBD care.Methods: Questionnaires were administered to IBD patients, advanced practice providers (APPs), and gastroenterologists throughout the United States from September through November 2023 on topics including access to care, IBD specialists, and MDTs. Statistical analyses included t-tests, chi-square tests, analysis of variance tests, and regression.Results: The analysis included 100 rural and 100 urban patients, 20 rural and 50 urban APPs, and 35 rural and 50 urban gastroenterologists. Rural patients were more likely to be receiving no therapy for IBD and less likely to receive advanced therapies (P = .001, P < .001, respectively). Rural patients reported less use of IBD multidisciplinary care and providers identified reduced access to multidisciplinary providers for rural patients. All patients had high interest in maintaining relationships with their current IBD provider while receiving care through a consulting MDT. Providers expressed strong interest in MDTs, with rural gastroenterologists reporting greater interest than urban gastroenterologists (P = .004).Conclusions: These results demonstrate disparities between rural and urban patients' treatments and access to specialty IBD care. Rural patients and providers are supportive of collaborating with IBD specialists and MDTs. These results can help guide the implementation of innovative IBD care models in the setting of an increasingly complex IBD landscape.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AI-Assisted IBD Severity Classification: A Critical Perspective on Current Evidence and Next Steps. 人工智能辅助IBD严重程度分类：当前证据和下一步的关键观点。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-08 DOI: 10.1093/ibd/izaf103

Shubham Kumar, Rachana Mehta, Ranjana Sah

引用次数: 0

Crohn's Disease Stricture Response to Treatment Assessed with Magnetic Resonance Imaging and Intestinal Ultrasound: STRIDENT Randomized Trial. 用磁共振成像和肠道超声评估克罗恩病狭窄治疗反应：STRIDENT随机试验。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-08 DOI: 10.1093/ibd/izaf073

Grace C Lovett, Julien D Schulberg, Amy L Hamilton, Emily K Wright, Tom R Sutherland, Alyson L Ross, Michael A Kamm

{"title":"Crohn's Disease Stricture Response to Treatment Assessed with Magnetic Resonance Imaging and Intestinal Ultrasound: STRIDENT Randomized Trial.","authors":"Grace C Lovett, Julien D Schulberg, Amy L Hamilton, Emily K Wright, Tom R Sutherland, Alyson L Ross, Michael A Kamm","doi":"10.1093/ibd/izaf073","DOIUrl":"https://doi.org/10.1093/ibd/izaf073","url":null,"abstract":"Background: Transmural healing is emerging as a key treatment target in Crohn's disease. This study aimed to determine the role of magnetic resonance imaging (MRI) and intestinal ultrasound (IUS) in the assessment of the radiologic response of Crohn's disease strictures to treatment.Methods: The STRIDENT (Stricture Definition and Treatment) study was a randomized controlled trial of (2:1) intensive high-dose adalimumab combined with a thiopurine vs standard dose monotherapy adalimumab in patients with stricturing Crohn's disease. Clinical response was defined as a reduction in the Obstructive Symptom Score at 12 months. Intestinal ultrasound was performed at baseline, 4, 8, and 12 months and MRI at baseline and 12 months. This study examines secondary outcomes of stricture resolution and changes in stricture morphology with treatment.Results: Of 77 patients, 52 were in the intensive treatment group and 25 in the standard therapy group. Clinical response was achieved in 56 of 77 patients (73%). Complete stricture resolution occurred in 17 patients on IUS (29%) and 16 patients on MRI (22%). Stricture improvement occurred in 23 of 59 patients on IUS (39%) and 24 of 72 patients on MRI (33%). Bowel wall thickness improved at 12 months on both IUS (P < .0001) and MRI (P < .001) and was significantly lower in clinical responders (IUS P = .003) and those with fecal calprotectin < 100 µg/g (IUS P < .001; MRI P = .001).Conclusions: Radiologic severity of Crohn's disease strictures can improve with drug treatment, with complete stricture resolution observed in some. Intestinal ultrasound and MRI are effective modalities for monitoring the treatment response in patients with stricturing Crohn's disease (STRIDENT Drug Therapy Study: NCT03220841).","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monitoring Structural Bowel Damage in Patients With Crohn's Disease Using Intestinal Ultrasonography: Can It Be Reversed by Biological Treatment? 利用肠道超声监测克罗恩病患者的结构性肠损伤：生物治疗可以逆转吗？

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-08 DOI: 10.1093/ibd/izaf100

Sara Albert, Pilar Marqués, Ángela Algarra, Esther Blanc, María Jesús Pérez, José Richart, José María Paredes

{"title":"Monitoring Structural Bowel Damage in Patients With Crohn's Disease Using Intestinal Ultrasonography: Can It Be Reversed by Biological Treatment?","authors":"Sara Albert, Pilar Marqués, Ángela Algarra, Esther Blanc, María Jesús Pérez, José Richart, José María Paredes","doi":"10.1093/ibd/izaf100","DOIUrl":"10.1093/ibd/izaf100","url":null,"abstract":"Background: Currently, medical therapy of Crohn's disease (CD) can reduce the progression of some forms of structural bowel damage (SBD), but it does not prevent it. Once SBD has developed, it is important to assess the potential of medical treatments to reverse this damage.Aims: To determine whether transmural healing (TH), assessed by intestinal ultrasonography (IUS), can be achieved with medical treatment in CD patients with SBD compared to those without.Methods: A prospective, longitudinal, observational study was conducted to compare IUS monitoring at 3 and 12 months of treatment between CD patients with SBD prior to treatment and those with an inflammatory pattern.Results: Three months after starting treatment, patients without SBD had a significantly higher TH rate than those with SBD (25.8% vs 7.8%, respectively; P = .004). However, after 12 months, the TH rate was not significantly higher in patients without SBD compared to those with SBD (34% vs 26.6%, respectively; P = .317). During these 12 months, the need for corticosteroids, hospitalizations, and surgical resection was significantly higher in the SBD group.Conclusions: Biological treatment can reverse SBD in CD, but hospitalizations and surgery rates remain higher in this group.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to the Letter to the Editor: "AI-Assisted IBD Severity Classification: A Critical Perspective on Current Evidence and Next Steps". 对致编辑的信的回复：“人工智能辅助IBD严重程度分类：当前证据和下一步的关键观点”。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-07 DOI: 10.1093/ibd/izaf096

Michelle Chae Min Lee, Armin Farahvash, Petros Zezos

引用次数: 0

Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response. 抗肿瘤坏死因子药物监测和反应丧失的即时检测的临床效用和准确性。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-07 DOI: 10.1093/ibd/izaf101

Christoph Teichert, Suzanne I Anjie, Toer W Stevens, Bayda Bahur, Kurtis R Bray, Krisztina B Gecse, Geert R D'Haens

{"title":"Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response.","authors":"Christoph Teichert, Suzanne I Anjie, Toer W Stevens, Bayda Bahur, Kurtis R Bray, Krisztina B Gecse, Geert R D'Haens","doi":"10.1093/ibd/izaf101","DOIUrl":"https://doi.org/10.1093/ibd/izaf101","url":null,"abstract":"Background and aims: Point-of-care tests (POCT) enable immediate measurement of anti-TNF blood concentrations. This study examined the association between loss of response (LOR) to infliximab (IFX) or adalimumab (ADL) and serum concentrations measured with POCT and enzyme-linked immunosorbent assay (ELISA) in inflammatory bowel disease (IBD) patients.Methods: Patients with IBD with stored IFX or ADL serum samples were recruited. POCT was conducted, agreement with ELISA was evaluated using Bland-Altman plots. The primary endpoint was LOR defined as change in therapy, IBD-related surgery, new actively draining fistula, and/or endoscopic deterioration. ROC curves and quartile analysis assessed the association between concentrations and LOR.Results: A total of 176 patients were included (92 IFX/84 ADL, 154 Crohn's disease, and 22 ulcerative colitis). Median follow-up time was 20 months (interquartile range 9-38). LOR occurred in 37/84 (44%) ADL users and 55/92 (60%) IFX users. Median serum concentrations were significantly lower in LOR patients compared with sustained response, measured by both techniques for ADL (POCT: 6.45 vs 13.48 µg/mL, P <.001; ELISA: 4.80 vs 8.80 µg/mL, P <.001) and IFX (POCT: 2.39 vs 6.50 µg/mL, P <.001; ELISA: 1.70 vs 4.40 µg/mL, P <.001). Quartile analysis revealed that higher serum concentrations were associated with maintained response. ROC curve analysis demonstrated good or excellent discrimination for POCT and ELISA in association with LOR (AUC IFX: POCT = 0.82, ELISA = 0.76; AUC ADL: POCT = 0.82, ELISA = 0.81; all P <.0001). An overestimation of serum concentrations with POCT was observed.Conclusions: Serum ADL and IFX POCT concentrations are comparable to ELISA and associated with LOR, indicating its clinical utility.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding Pouch-Related Fistulae: Don't Lose Track of Time. 了解与眼袋有关的瘘管：不要忘记时间。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-07 DOI: 10.1093/ibd/izaf084

Sergio Bronze, Serre-Yu Wong, Haley Waite, Sergey Khaitov, Michael Plietz, Sue Hahn, Alexander Greenstein, Patricia Sylla, Jean-Frederic Colombel, Maia Kayal

引用次数: 0

Non-Typhoidal Salmonella Infections and Inflammatory Bowel Disease Risk: New Findings and Multidimensional Perspectives for Future Research. 非伤寒沙门氏菌感染和炎症性肠病风险：新发现和未来研究的多维视角。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-05 DOI: 10.1093/ibd/izaf082

Yichen Feng, Shengfeng Wang, Sheng Li

引用次数: 0

The Way Forward in the Diagnosis and Treatment of IBDU in Children: A Global Perspective and Multidimensional Exploration. 儿童IBDU诊断和治疗的前进之路：全球视角和多维探索。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-05 DOI: 10.1093/ibd/izaf104

Guilin Bai, Shengfeng Wang, Yuexia Zhang

引用次数: 0

Multifaceted Endoscopic Approach (Stricturotomy, Balloon Dilation, Fistulotomy, and Seton Placement) Guided by Intestinal Ultrasound to Avert Surgery in Complicated Crohn's Disease During Lactation. 多面内镜入路（狭窄切开术、球囊扩张术、瘘管切开术和塞顿置入术）在肠道超声引导下避免哺乳期复杂克罗恩病的手术。